2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis.
The 2024 ACR guideline for lupus nephritis reframes therapy as a continuous process rather than separate induction and maintenance phases, recommending pulse glucocorticoids followed by an oral taper plus two additional immunosuppressive agents for 3 to 5 years in patients achieving complete renal response.